NCT06365619招募中2 期
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery.
研究概览
简要总结
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.
Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged ≥ 18 years.
- •Histologically confirmed Stage IIIB-D or Stage IV recurrent metastatic melanoma that is resectable or borderline resectable as determined by a Surgical Oncologist.
- •Recurrent disease at eligibility must have been confirmed with biopsy after receiving prior anti-PD1 based systemic therapy (either adjuvant, neoadjuvant, or definitive therapy).
- •ECOG Performance Status ≤
- •Adequate organ function as defined as:
- •Hematologic:
- •Absolute neutrophil count (ANC) ≥ 1500/mm3
- •Platelet count ≥ 100,000/mm3
- •Hemoglobin ≥ 10 g/dL
- •Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN
- •Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
- •Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula:
- •For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- •Subjects < 50 years of age:
- •Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
- •Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
- •Subjects ≥ 50 years of age:
- •Amenorrheic for ≥ 12 months following cessation of all exogenous hormonal treatments; or
- •Had radiation-induced menopause with last menses >1 year ago; or
- •Had chemotherapy-induced menopause with last menses >1 year ago
- •Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.
- •Recovery to baseline or ≤ Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator.
- •Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
排除标准
- •Prior exposure to anti-CTLA4 therapy.
- •Receiving other investigational agents currently or within 28 days of study treatment.
- •Prior systemic anti-cancer therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.
- •Prior radiotherapy 45 days prior to the first dose of study treatment.
- •Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.
- •Active infection requiring the use of systemic antibiotics.
- •Systemic steroid therapy greater than physiologic equivalent (10mg prednisone/day) or any other form of systemic immunosuppressive therapy within 7 days prior to registration.
- •Active secondary malignancy, unless the malignancy is not expected to interfere with the evaluation of safety
- •Known brain metastases or cranial epidural disease.
- •Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
- •Cardiovascular disorders:
- •Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.
- •Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.
- •QTc prolongation defined as a QTcF > 500 ms.
- •Known congenital long QT.
- •Left ventricular ejection fraction < 55%.
- •Uncontrolled hypertension defined as ≥ 140/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.
- •Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/psychological issues, etc.)
- •HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.
- •-Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (positive HBV surface antigen (HBsAg) result), or hepatitis C.
- •-Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.
- •Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).
- •Subjects taking prohibited medications as described in Section 6.7.
- •A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.
研究组 & 干预措施
Treatment: All Patients
Experimental
Neoadjuvant Ipilimumab and Nivolumab
干预措施: Ipilimumab (Drug)
Treatment: All Patients
Experimental
Neoadjuvant Ipilimumab and Nivolumab
干预措施: Nivolumab (Drug)
结局指标
主要结局
Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery.
时间窗: 2 months
Assess the pathologic response rate (pRR) at the time of surgery after two doses of neoadjuvant Ipilimumab and Nivolumab for patients with resectable disease that have recurred after receiving systemic anti-PD1 therapy.
次要结局
- Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.(2 months)
- Rate of Event Free Survival (EFS).(11 years)
- Rate of Overall Survival (OS).(11 years)
- Rate of adverse events that occur within 30 days post-surgery.(30 days)
- Objective response rate (ORR) defined as the proportion of subjects achieving a confirmed PR and CR as defined by RECIST 1.1 prior to surgical resection.(11 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerLocally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8NCT04751370National Cancer Institute (NCI)31
已完成
1 期
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorNerve Sheath TumorsNCT04465643Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13
已完成
2 期
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)Prostate CancerNCT02985957Bristol-Myers Squibb351
已完成
2 期
Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsPituitaryPituitary CarcinomaPituitary CancerPituitary TumorNCT04042753Memorial Sloan Kettering Cancer Center10
已完成
2 期
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaMetastatic LeiomyosarcomaUnresectable LeiomyosarcomaUterine Corpus LeiomyosarcomaNCT02428192National Cancer Institute (NCI)20